The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity

Expert Opinion on Investigational Drugs

Volumn 14, Issue 5, 2005, Pages 647-653

  Small, Caroline J ^a   Bloom, Stephen R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Appetite; Gut hormones; Obesity; Peptide YY

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN; PEPTIDE YY; PEPTIDE YY [3-36]; PLACEBO; UNCLASSIFIED DRUG;

APPETITE; CALORIC INTAKE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG TOLERABILITY; FOOD INTAKE; GASTROINTESTINAL TRACT; HEADACHE; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HYPOTHALAMUS; NAUSEA; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PREVALENCE; REVIEW; UNITED KINGDOM; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; GASTROINTESTINAL HORMONES; HUMANS; OBESITY; PEPTIDE HORMONES; PEPTIDE YY;

EID: 20344389011     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.5.647     Document Type: Review

References (54)

1. BOURNE J: Tackling obesity in England. National Audit Office. (2001):1-72.
2. FOXCROFT DR, MILNE R: Orlistat for the treatment of obesity: rapid review and cost effectiveness model. (2000) 1:121-126.
3. STOCK MJ: 1997 Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int. J. Obes. Relat. Metab. Disord. (1997) 21(Suppl. 1):S25-S29.
4. FINER N: Sibutramine: its mode of action and efficacy. Int. J. Obes. Relat. Metab. Disord. (2002) 26 Suppl. 4:S29-S33.
5. FINER N: Pharmacotherapy of obesity. Best Pract. Res. Clin. Endocrinol. Metab. (2002) 16:717-742.
6. MITCHELL JE, LANCASTER KL, BURGARD MA et al.: Long-term follow-up of patients' status after gastric bypass. Obes. Surg. (2001) 11:464-468.
7. SARSON DL, SCOPINARO N, BLOOM SR: Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int. J. Obes. (1981) 5:471-480.
8. CUMMINGS DE, SHANNON MH: Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J. Clin. Endocrinol. Metab. (2003) 88:2999-3002.
9. CUMMINGS DE, WEIGLE DS, FRAYO RS et al.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. (2002) 346:1623-1630.
10. CUMMINGS DE, SHANNON MH: Roles for ghrelin in the regulation of appetite and body weight. Arch. Surg. (203) 138:389-396.
11. KOJIMA M, KANGAWA K: Ghrelin, an orexigenic signaling molecule from the gastrointestinal tract. Curr. Opin. Pharmacol. (2002) 2:665-668.
12. MORAN TH, SCHWARTZ GJ: Neurobiology of cholecystokinin. Crit. Rev. Neurobiol. (1994) 9:1-28.
13. BATTERHAM RL, COWLEY MA, SMALL CJ et al.: Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2004) 418:650-654.
14. 3-36. N. Engl. J. Med. (2003) 349:941-948.
15. 3-36? Expert Opin. Investig. Drugs (2004) 13:285-287.
16. COHEN MA, ELLIS SM, LE ROUX CW et al.: 2003 Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. (2003) 88:4696-4701.
17. BATTERHAM RL, LE ROUX CW, COHEN MA et al.: Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab. (2003) 88:3989-3992.
18. WREN AM, SMALL CJ, ABBOTT CR et al.: Ghrelin causes hyperphagia and obesity in rats. Diabetes (2001) 50:2540-2547.
19. WREN AM, SEAL LJ, COHEN MA et al.: Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. (2001) 86:5992.
20. SCHWARTZ MW, WOODS SC, PORTE D Jr, SEELEY RJ, BASKIN DG: Central nervous system control of food intake. Nature (2000) 404:661-671.
21. KALRA SP, DUBE MG, PU S, XU B, HORVATH TL, KALRA PS: Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. (1999) 20:68-100.
22. CONE RD, COWLEY MA, BUTLER AA, FAN W, MARKS DL, LOW MJ: The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int. J. Obes. Relat. Metab. Disord. (2001) 2(Suppl. 5):S63-S67.
23. COWEY MA, CONE RD, ENRIORI P, LOUISELLE I, WILLIAMS SM, EVANS AE: Electrophysiological actions of peripheral hormones on melanocortin neurons. Ann. NY Acad. Sci. (2003) 994:175-186.
24. BARSH GS, FAROOQI IS, O'RAHILLY S: Genetics of body-weight regulation. Nature (2000) 404:644-651.
25. O'RAHILLY S: Life without leptin. Nature (1998) 392:330-331.
26. TATEMOTO K, MUTT V: Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature (1980) 285:417-418.
27. HOYLE CH: Neuropeptide families and their receptors: evolutionary perspectives. Brain Res. (1999) 848:1-25.
28. LARHAMMAR D: Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. (1996) 65:165-174.
29. BALASABRUMANIAM AA: Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides (1997) 18:445-457.
30. CLAUSTRE J, BRECHET S, PLAISANCIE P, CHAYVIELLE JA, CUBER JC: Stimulatory effect of β-adrenergic agonists on ileal L cell secretion and modulation by α-adrenergic activation. J. Endocrinol. (1999) 162:271-278.
31. ADRIAN TE, FERRI GL, BACARESE-HAMILTON AJ, FUESSL HS, POLAK JM, BLOOM SR: Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology (1985) 89:1070-1077.
32. EKBLAD E, SUNDLER F: Distribution of pancreatic polypeptide and peptide YY. Peptides (2002) 23:251-261.
33. OKADA S, OHSHIMA K, MORI M, TATEMOTO K: Peripheral not central administered PYY decreases high fat diet intake. (1993):180.
34. BATTERHAM RL, BLOOM SR: The gut hormone peptide YY regulates appetite. Ann. NY. Acad. Sci. (2003) 994:162-168.
35. MARTIN NM, SMALL CJ, SAJEDI A, PATTERSON M, GHATEI MA, BLOOM SR: Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin. Int. J. Obes. Relat. Metab. Disord. (2004) 28:886-893.
36. 3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology (2004) 145:2585-2590.
37. 3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem. Biophys. Res. Commun. (2003) 311:915-919.
38. 3-36-induced feeding reduction in rats. Endcrinology (2005).
39. CORP ES, MELVILLE LD, GREENBERG D, GIBBS J, SMITH GP: Effect of fourth ventricular neuropeptide Y and peptide YY on ingestive and other behaviors. Am. J. Physiol. (1990) 259:R317-R323.
40. O'SHEA D, MORGAN DG, MEERAN K et al.: Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology (1997) 138:196-202.
41. STANLEY BG, LEIBOWITZ SF: Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proc. Natl. Acad. Sci. USA (1985) 82:3940-3943.
42. HAGAN MM, CASTANEDA E, SUMAYA IC, FLEMING SM, GALLOWAY J, MOSS DE: The effect of hypothalamic peptide YY on hippocampal acetylcholine release in vivo: implications for limbic function in binge-eating behavior. Brain Res. (1998) 805:20-28.
43. 5 receptor-deficient mice. Endocrinology (2000) 141:1011-1016.
44. 3-36 decrease food intake in rodents? Nature (2004) 430:1.
45. CHALLIS BG, COLL AP, YEO GS et al.: Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc. Natl. Acad. Sci. USA (2004) 101:4695-4700.
46. MORAN TH, SMEDH U, KINZIG KP, SCOTT KA, KNIPP S, LADENHEIM EE: Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 288:R384-R388.
47. RIEDIGER T, BOTHE C, BECSKEI C, LUTZ TA: Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology (2004) 79:317-326.
48. COX JE, RANDICH A: Enhancement of feeding suppression by PYY(3-36) in rats with area postrema ablations. Peptides (2004) 25:985-989.
49. ONAGA T, ZABIELSKI R, KATO S: Multiple regulation of peptide YY secretion in the digestive tract. Peptides (2002) 23:279-290.
50. FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1998) 395:763-770.
51. TSCHOP M, WEYER C, TATARANNI PA, DEVANARAYAN V, RAVUSSIN E, HEIMAN ML: Circulating ghrelin levels are decreased in human obesity. Diabetes (2001) 50:707-709.
52. BEDNAREK MA, FEIGHNER SD, PONG SS et al.: Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. (2000) 43:4370-4376.
53. NASHUND E, GRYBACK P, HELLSTROM PM et al.: Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int. J. Obes. Relat. Metab. Disord. (1997) 21:387-392.
54. LE ROUX CW, SHUREY S, GHATEI MA, BLOOM SR: PYY and decreased appetite following jejunum intestinal bypass in rats. (2003).